差示扫描量热法
葡萄激酶
化学
动态光散射
吸热过程
分散性
放热反应
热稳定性
圆二色性
变性(裂变材料)
动力学
生物物理学
结晶学
背景(考古学)
立体化学
连接器
胶体
化学工程
折叠(DSP实现)
理论(学习稳定性)
免疫原性
材料科学
作者
Michal Nemergut,Monika Štulajterová,Rostislav Škrabana,Andrej Hovan,Ľuboš Ambro,Alan Strunga,Zbyněk Prokop,Jiří Damborský,Mária Tomková,Erik Sedlák
出处
期刊:Protein Science
[Wiley]
日期:2026-02-12
卷期号:35 (3): e70494-e70494
被引量:2
摘要
Staphylokinase (SAK) is a promising third-generation thrombolytic protein, but its clinical potential is limited by immunogenicity and stability concerns. The conformational and colloidal stabilities of four SAK variants-SAK 42D, SAK STAR, and their non-immunogenic derivatives SAK 42D 3A and SAK STAR 3A-were evaluated using differential scanning calorimetry (DSC), dynamic light scattering (DLS), and aggregation kinetics assays. DSC analyses revealed that thermal denaturation of all variants proceeds via two consecutive irreversible steps, with transition parameters strongly dependent on scan rate and protein concentration. SAK STAR variants exhibited markedly exothermic first transitions and reduced scan rate dependence, suggesting stabilization of intermediate states and suppression of aggregation. In contrast, SAK 42D variants exhibited endothermic or weakly exothermic first transitions and a higher aggregation propensity, correlating with reduced conformational stability and formation of less stable dimers. Colloidal stability tests showed that SAK STAR and SAK STAR 3A remained largely aggregation-resistant, whereas SAK 42D and SAK 42D 3A aggregated rapidly at elevated temperatures (>51°C and >38°C, respectively), following apparent second-order kinetics. DLS confirmed concentration-dependent dimerization in all variants, with SAK 42D 3A displaying pronounced polydispersity and instability. We could rationalize this behavior in the context of engineered surface charges. Our results demonstrate that SAK variant stability is shaped by a complex interplay between primary sequence, dimerization behavior, and aggregation propensity, guiding the design of clinically viable thrombolytic agents and their formulations.
科研通智能强力驱动
Strongly Powered by AbleSci AI